Category: vials
-
Hims & Hers Health declines as Lilly launches single-dose vials of Zepbound By Investing.com
•
Shares of Hims & Hers Health fell more than 6% Tuesday morning in response to Eli Lilly’s (NYSE:) latest announcement. Lilly announced that it has launched single-dose vials of its obesity drug, Zebound, at a 50% discount to other incretins, a move that comes amid growing competition in the obesity…